EMA Authorised: Tezspire (tezepelumab) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Tezspire (tezepelumab) by AstraZeneca AB for the treatment of asthma and sinusitis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Sinusitis

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Status: Authorised. Therapeutic area: Asthma;Sinusitis. MAH: AstraZeneca AB. Decision date: 20/10/2025